How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

automation
Episode 2 Promo: How Vecna Robotics Keeps Automation Aligned with the Floor
May 10, 2025

The second episode of Robot vs. Wild features David Rabinovic, Vice President of Deployment at Vecna Robotics, and Josh Kivenko, Chief Marketing Officer, in a conversation about the ever-changing nature of warehouse environments and what it takes to keep automation aligned with reality. Unlike manufacturing, where operations follow predictable cycles, warehouses are dynamic ecosystems—shifting every…

Read More
Robotics
Episode 3 Promo: Inside Vecna Robotics’ Mission to Build Safer Automated Warehouses
May 9, 2025

The third episode of Robot vs. Wild takes a close look at one of the most critical success factors in automation: robot safety. Featuring Michael Bearman, Chief Legal & Safety Officer, and Josh Kivenko, Chief Marketing Officer at Vecna Robotics, this episode explores why safety in automation isn’t just about the robots—it’s about people, processes,…

Read More
Vecna Robotics
Episode 4 Promo: How Vecna Robotics Connects Tech and Strategy for Smarter Automation
May 9, 2025

Episode four of Robot vs. Wild features a conversation between Zachary Dydek, Chief Technology Officer at Vecna Robotics, and Josh Kivenko, the company’s Chief Marketing Officer. The episode explores the advanced technologies behind Vecna’s automation solutions and how engineering and marketing align to deliver scalable, human-centered innovation. Topics include real-time orchestration, autonomous systems, and how…

Read More
automation
Episode 5 Promo: There Are No Bad Robots, Only Bad Owners
May 9, 2025

What really makes or breaks a robotics deployment? Spoiler: it’s not the robot. In the fifth episode of Robot vs. Wild, Vecna Robotics’ Chief Marketing Officer Josh Kivenko and Customer Success Manager Ty LaFramboise reveal why successful automation is less about machines—and more about mindset. From aligning corporate goals with floor-level operations, to helping teams adjust to new…

Read More